Q32 Bio, a biotech company developing treatments for alopecia areata and autoimmune diseases, will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is advancing bempikibart, an antibody therapy in Phase 2 trials targeting immune regulation for alopecia areata, a condition affecting 700,000 people in the U.S. This presentation highlights Q32 Bio's progress and commitment to innovative therapies in immune-related diseases. A webcast will be available on their website with a replay for 90 days.
Q32 Bio's upcoming participation in the 2026 Jefferies Global Healthcare Conference offers context for healthcare sector activity. For readers following healthcare stocks, here is Pluang's market snapshot as of Nov 11, 2026 19:11 WIB: Among 150 priced US health-sector stocks, 67 rose and 75 fell. Notable movers include Twist Bioscience Corp (TWST) at USD 141.14 with a 6.82% increase and a typical hold time of 27 days, Tango Therapeutics Inc. (TNGX) at USD 23.00 down 5.35% with a 4-day hold time and balanced order activity, and InMode Ltd (INMD) at USD 13.85 up 4.41% with a 34-day hold time.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
